Intuitive Surgical (NASDAQ:ISRG) Issues Quarterly Earnings Results

Intuitive Surgical (NASDAQ:ISRG) posted its earnings results on Thursday. The medical equipment provider reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24, Briefing.com reports. Intuitive Surgical had a return on equity of 13.40% and a net margin of 27.65%. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the previous year, the firm earned $1.18 EPS. The company’s quarterly revenue was up 14.5% compared to the same quarter last year.

Intuitive Surgical Stock Up 9.3 %

Shares of ISRG opened at $455.01 on Friday. Intuitive Surgical has a 52 week low of $254.85 and a 52 week high of $456.81. The stock has a market cap of $161.39 billion, a P/E ratio of 82.13, a P/E/G ratio of 5.37 and a beta of 1.39. The business’s 50 day moving average price is $422.05 and its 200-day moving average price is $393.77.

Insider Activity at Intuitive Surgical

In other news, SVP Mark Brosius sold 175 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the sale, the senior vice president now directly owns 883 shares of the company’s stock, valued at $343,628.28. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, SVP Mark Brosius sold 175 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $389.16, for a total transaction of $68,103.00. Following the sale, the senior vice president now owns 883 shares in the company, valued at $343,628.28. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total value of $1,971,169.88. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at $110,456.68. The disclosure for this sale can be found here. Insiders sold a total of 17,956 shares of company stock valued at $6,927,011 in the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. The Goldman Sachs Group started coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Piper Sandler increased their price target on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday. Citigroup boosted their target price on Intuitive Surgical from $462.00 to $512.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Barclays raised their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Jefferies Financial Group upped their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $438.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.